The investigational PANXEON liquid biopsy detected early-stage pancreatic cancer with 87% sensitivity and low false-positive rates in a multi-center study of nearly 1,800 patients.
ClearNote Health and University Hospital Southampton have launched the SAFE-D study to evaluate the Avantect Pancreatic Cancer Test.
PharusDx announced a liquid biopsy test that uses microRNA and CA19-9 biomarkers to detect early-stage pancreatic cancer.
Immunovia has been selected for a US-government-funded study to evaluate biomarker tests for monitoring pancreatic cystic neoplasms.
Read More
Immunovia’s new lab is now fully operational, marking a significant step towards enhancing early detection of pancreatic cancer.
Read More
Immunovia’s new pancreatic cancer test demonstrated a specificity of 98% and a sensitivity of 75% for early-stage 1 and 2 pancreatic cancers.
Read More
Researchers applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism.
Read More
Immunovia, a company focused on pancreatic cancer detection, successfully completed of the discovery phase of its next-generation test.Â
Read More
The AMA issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Pancreatic Cancer Test.Â
Read More
Amplified Sciences will use the grant money to develop a test to determine if pancreatic cysts are benign or potentially malignant.
Read More
An artificial intelligence tool has successfully identified those at the highest risk for pancreatic cancer up to 3 years before diagnosis.
Read More
Singlera Genomics’ PDACatch assay is a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.
Read More
A research team identified biomarkers that could help distinguish whether cysts on the pancreas will develop into cancer or remain benign.
Read More
Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Read More
New research points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer.
Read More
Bluestar Genomics announced the results of a validation study for its early pancreatic cancer detection test. Â
Read More
Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests.
Read More
The CAP certification enables Bluestar to serve physicians as it works towards broad commercialization of its pancreatic cancer test.Â
Read More